The Viability of Emerging Public and Private Generic Drug Infrastructure in India: An in-vitro Case Study Using Statins as Model Drug

Abstract

The healthcare system has been fundamentally altered by the introduction of generic medications, and their market share continues to rise because these are genuine, dependable, secure, affordable, and accessible to all the needy and poor in society. In this regard, the generic drug industry, which strives for authenticity, affordability, and accessibility, plays a significant role. Using HMG CoA reductase inhibitors (Atorvastatin and Rosuvastatin) as model drugs, the study aimed to determine the viability of the emerging public and private generic drug infrastructure in India, which included Janaushadhi, Dava India, and other assorted companies. The organoleptic properties and official and non-official quality control tests were evaluated. According to the in-vitro dissolution profiles, the Mankind brand of atorvastatin has shown the highest dissolution profile (75.29%), and the Dava India brand of rosuvastatin has the maximum drug release (97.26%) in one hour release. The Peppas model best explained the drug release model, which inferred the release profile to be diffusion-specific. The compatibility analysis of the tablet formulation has been shown through FTIR studies. These results concluded that public generic drugs are as effective as private generic drugs, and patients can easily take the cost-effective brand of medication.